regulatory subunit of type II PKA R-subunit domain containing 1Genealiases: C1orf230 · NCRNA00166
Q-omics provides the consensus-scored RIIAD1 profile across patient tissues and cancer cell-line models. RIIAD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RIIAD1 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, RIIAD1 RNA expression shows 13,101 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LUAD, and GBM as cancer lineages where RIIAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIIAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIIAD1 survival associations across molecular data types. RIIAD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIIAD1 RNA expression–survival associations across cancer types. High RIIAD1 expression shows unfavorable associations in KIRC, but favorable associations in ACC, BLCA, THCA, UCEC and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RIIAD1 RNA expression.
This table summarizes RIIAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RIIAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIIAD1 shows lower tumor expression in LUAD, KICH, LUSC, HNSC and KIRC and higher tumor expression in BRCA. The LUAD box plot shows higher RIIAD1 RNA expression in normal versus tumor tissue (log2 FC = −1.152, t-test p < 0.001).
This table shows molecular features associated with RIIAD1 in patient tissues and cancer cell lines. In patient samples, RIIAD1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RIIAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BREAST.
